2024
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma
Caimi P, Huntington S, Landrette S, Gough S, Dai V, Jackson B, Yu T, Chavez J, Tannenbaum-Dvir S, Matasar M. Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood 2024, 144: 6505. DOI: 10.1182/blood-2024-208356.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaB-cell non-Hodgkin lymphomaDiffuse large B-cell lymphomaStem cell transplantationPhase 1 studyCell transplantationAdvanced B-cell non-Hodgkin's lymphomaB cellsMature B-cell non-Hodgkin lymphomaXenograft models of non-Hodgkin lymphomaBCL6 expressionEastern Cooperative Oncology Group performance statusModel of non-Hodgkin lymphomaAdvanced non-Hodgkin's lymphomaAllogeneic stem cell transplantationAngioimmunoblastic T-cell lymphomaAutologous stem cell transplantationLarge B-cell lymphomaNon-Hodgkin's lymphoma casesCell line-derived xenograft modelT follicular helper cellsPatient-derived xenograft modelsStandard of care therapyHigh risk of transformationCentral nervous system involvement
2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weekly